Development of Anti-SSTR CAR T Cells for Future Treatment of NETs Abstract #3004

Introduction: NETs overexpress somatostatin receptors (SSTRs).
Aim(s): To investigate the antitumor activity of chimeric antigen receptor (CAR) T cells directed against SSTRs.
Materials and methods: A second-generation CAR-like construct containing two molecules of octreotide in the extracellular moiety and CD28 as costimulatory module was cloned in a pMSGV1-28Z retroviral vector and then transduced in CD8+ T cells. Luciferase+ (Luc+) BON1, CM and QGP1 NET cells were screened for membrane SSTR2/5 expression by WB and flow cytometry. Co-culture experiments were performed at different effector:target (E:T) ratios for up to 48 hrs. Tumor cell cytotoxicity was assessed by bioluminescence imaging. The release of IFN-γ, IL-2 and TNF-α by activated CAR T cells was investigated by ELISA. NSG female mice (n=6/group) were subcutaneously injected with 4x106 Luc+ NET cells, and were then intravenously treated with 1x106 anti-SSTR CAR T cells, or untransduced (UT) T cells. Excised tumors were subjected to PCR to assess the infiltration of CAR T cells.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr. Mauro Cives

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1520 Osteotropism of NETs: Role of the SDF1/CXCR4 Axis in Regulating EMT
Introduction: NETs metastasize to the bone in up to 20% of patients. The SDF1/CXCR4 axis is a key determinant of osteotropism, and we showed that NETs overexpressing CXCR4 are more likely to develop bone metastases.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Valeria Simone
Keywords: emt, cxcr4
#2908 Re-Cellularised Human Pancreas 3D Scaffolds as a Novel Model for Biomarker Discovery in Pancreatic Neuroendocrine Tumours (pNETs)
Introduction: The lack of preclinical models of pNETs has challenged identification of tissue specific biomarkers of disease. Culturing cancer cells in their native tissue enables the close study of cell-ECM interaction and tissue remodelling. The biological products of such interactions can form a basis for discovery of novel biomarkers of the disease, and were previously linked with a range of inflammatory and malignant conditions.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: PhD student & CR Alexander Ney
#2875 Immunotherapy as Second-line Treatment in Grade 3 Neuroendocrine Carcinomas: A Prospective Case Series from an ENETS Center of Excellence
Introduction: Metastatic WHO grade 3 extra-pulmonary neuroendocrine carcinomas (EP-NEC) have a poor prognosis and optimal treatment after first-line platinum-etoposide chemotherapy remains unclear. A recent, small phase II study combining ipilimumab and nivolumab showed promising results
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Timon Vandamme
Keywords: NEC, immunotherapy
#1199 Tumor Infiltrating Lymphocytes and PD-L1 Expression Differ in Low and High Grade Neuroendocrine Tumors
Introduction: Although much progress has been made in the past 2-3 years in terms of understanding signaling pathways in gastroenteropancreatic neuroendocrine tumors (GEP-NENs), approved treatment options are still limited. Cancer Immunotherapy has been announced as the breakthrough of the year in 2013 and might become an integral part of the clinical management strategy for solid tumors including GEP-NENs. Therefore, to develop immunotherapeutic strategies against NENs we need to know which immune escape mechanisms are relevant in high and low grade NEC/NENs.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Biomarkers
Presenting Author: PD Dr. Patricia Grabowski
#1847 CXCR4 Inhibition by Ulocuplumab Prevents EMT of pNET Cells in Vitro
Introduction: Neuroendocrine tumors (NETs) overexpress CXCR4. We have previously shown that stimulation of CXCR4 by its ligand SDF-1 promotes the epithelial-mesenchymal transition (EMT) and increases distant tumor spread. Ulocuplumab (Ulo) is a fully human IgG4 mAb designed to inhibit the binding of CXCR4 to SDF-1.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr. Mauro Cives
Keywords: pNET, CXCR4, EMT, Ulocuplumab